A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol

Abstract Introduction Relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) remains a therapeutic challenge. Preclinical data in both B‐ and T‐ALL suggests synergy of venetoclax (VEN) with vincristine (VCR). We designed a phase I/II trial (EA9152) of the comb...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Neil D. Palmisiano, Ju‐Whei Lee, David F. Claxton, Elisabeth M. Paietta, Hassan Alkhateeb, Jae Park, Nikolai A. Podoltsev, Ehab L. Atallah, Dale G. Schaar, Shira N. Dinner, Jonathan A. Webster, Selina M. Luger, Mark R. Litzow
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2024-10-01
Ráidu:	eJHaem
Fáttát:	acute leukaemia BCL‐2 clinical trials
Liŋkkat:	https://doi.org/10.1002/jha2.991
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!